<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Roflumilast (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Roflumilast (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Roflumilast (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="139318" href="/d/html/139318.html" rel="external">see "Roflumilast (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57077601"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Daliresp</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57077710"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Daxas</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57077606"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Phosphodiesterase-4 Enzyme Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F57077643"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="816318ee-927a-4bf7-8350-4ac96db9152a">Chronic obstructive pulmonary disease, prevention of exacerbations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, prevention of exacerbations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for patients with frequent exacerbations (eg, ≥1 hospital admission per year) despite optimal medical management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 mcg once daily for 4 weeks, followed by 500 mcg once daily. The initial dose of 250 mcg once daily is recommended for the first 4 weeks of treatment in an attempt to improve tolerability. However, this is not considered a therapeutic dose and the effect of this approach on long-term tolerability is uncertain.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57077586"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F57077585"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F57077644"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57077616"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">2% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (4%), dizziness (2%), insomnia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (5% to 10% of body weight: 8% to 20%; &gt;10% loss: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (10%), nausea (5%), decreased appetite (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;2%, postmarketing, and/or case reports: Abdominal pain, anemia, anxiety, arthralgia, arthritis, atrial fibrillation, constipation, depression, dysgeusia, dyspepsia, epistaxis, fatigue, gastritis, gastroesophageal reflux disease, gynecomastia, hematochezia, hypersensitivity, hypersensitivity reaction (including angioedema, urticaria, and rash), increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum AST, limb pain, lung carcinoma, malaise, muscle spasm, myalgia, myasthenia, nervousness, pancreatitis, paresthesia, prostate carcinoma, renal failure, respiratory tract infection, rhinitis, sinusitis, suicidal ideation, suicidal tendencies, suicide, supraventricular cardiac arrhythmia, tremor, urinary tract infection, vertigo, vomiting, weakness</p></div>
<div class="block coi drugH1Div" id="F57077613"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe hepatic impairment (Child-Pugh class B or C).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to roflumilast or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57077614"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric: Neuropsychiatric effects (eg, anxiety, depression, insomnia) have been reported with use; rarely, suicidal behavior/ideation and completed suicide were reported. Assess risk versus benefits before prescribing in patients with a history of depression with suicidal behavior/ideations; instruct patients/caregivers to report psychiatric symptoms and consider discontinuation of therapy in such patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight loss: Weight loss has occurred; monitor weight regularly. If unexplained or significant weight loss occurs, discontinuation should be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild impairment (systemic exposure may be increased); use in moderate to severe impairment is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for relieving acute bronchospasm.</p></div>
<div class="block foc drugH1Div" id="F57077654"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daliresp: 250 mcg, 500 mcg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mcg, 500 mcg</p></div>
<div class="block geq drugH1Div" id="F57077604"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F57077658"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Daliresp Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $17.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg (per each): $17.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Roflumilast Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $15.51 - $15.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg (per each): $1.20 - $15.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57077711"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Daxas: 500 mcg [contains corn starch]</p></div>
<div class="block adm drugH1Div" id="F57077645"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block meg drugH1Div" id="F57077598"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F022522s006lbl.pdf%23page%3D16&amp;token=m%2BgiqyXXKmnJnVxeJxF%2BPPnMtb4Iw7nKjOn8H5y82xB56ovMGHCjAy2tcGC4m98QCkA8t%2Bg9w6N7bcWDx7Le7IFWkVhzyv8k5h7fwsevtJAXMRdIYiS4PSYtcQzsbF3p&amp;TOPIC_ID=139288" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022522s006lbl.pdf#page=16</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F57077609"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease (COPD), prevention of exacerbations:</b> To reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for the relief of acute bronchospasm.</p></div>
<div class="block cyt drugH1Div" id="F57077622"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F57077619"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Cimetidine may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: May increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Ethinyl Estradiol-Containing Products may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. FluvoxaMINE may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Roflumilast-Containing Products may enhance the hypotensive effect of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Viloxazine may increase the serum concentration of Roflumilast-Containing Products.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F57077610"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F57077611"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if roflumilast is present in breast milk; however, excretion into human breast milk is likely. Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F57077647"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests; weight (regularly during therapy); new or worsening insomnia, anxiety, depression, suicidal thoughts, or other mood changes.</p></div>
<div class="block pha drugH1Div" id="F57077627"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase-4 (PDE4) leading to an accumulation of cyclic AMP (cAMP) within inflammatory and structural cells important in the pathogenesis of COPD. Anti-inflammatory effects include suppression of cytokine release and inhibition of lung infiltration by neutrophils and other leukocytes. Pulmonary remodeling and mucociliary malfunction are also attenuated.</p></div>
<div class="block phk drugH1Div" id="F57077628"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 2.9 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%; N-oxide metabolite: 97%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and CYP1A2 to active N-oxide metabolite; also undergoes conjugation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~80%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 17 hours; N-oxide metabolite: 30 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour (delayed by food); N-oxide metabolite: ~8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~70% as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F57077629"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe renal impairment, roflumilast and N-oxide metabolite AUCs were decreased by 21% and 7%, respectively, and C<sub>max</sub> was reduced 16% and 12%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The AUC of roflumilast and the N-oxide metabolite were increased by 51% and 24%, respectively, in Child-Pugh class A subjects and by 92% and 41%, respectively, in Child-Pugh class B subjects as compared with healthy subjects. The C<sub>max</sub> of roflumilast and the N-oxide metabolite was increased by 3% and 26%, respectively, in Child-Pugh class A subjects and by 26% and 40%, respectively, in Child-Pugh class B subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The roflumilast AUC and C<sub>max</sub> increased 27% and 16%, respectively, and the N-oxide metabolite AUC and C<sub>max</sub> increased 19% and 13%, respectively, in elderly patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: The roflumilast and N-oxide metabolite AUC increased 39% and 33%, respectively, in healthy women when compared with healthy men.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: The AUC and C<sub>max</sub> of roflumilast and the N-oxide metabolite increased in white, black, Hispanic, and Japanese patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: The AUC of roflumilast in smokers was 13% less than in nonsmokers while the AUC of the N-oxide metabolite in smokers was 17% more than in nonsmokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847689"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Rofluma | Roflumilast accord</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dilarof | Lumast | Milast a | Roflast | Romilast | Roxair</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Roflumilast accord | Roflumilast aurovitas | Rumixafen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Roflumilast accord</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andomilast | Westabreath</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Libertek | Roflumilast aurovitas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Damirast | Daxas</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Forespi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Exalbic | Rofaday | Roflair | Rofluren | Rofluz | Rofmil | Rofum | Rofurest | Rufus</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lemitat</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Daxxas</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Roflumilast accord</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Milast | Raxus | Rocop | Roflast | Romast | Romilast | Suntra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Daliresp</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Roflast</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Roflumilast 2care4 | Roflumilast accord</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Daxas | Rumixafen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Daxas</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19716960">
<a name="19716960"></a>Calverley PM, Rabe KF, Goehring UM, et al, “Roflumilast in Symptomatic Chronic Obstructive Pulmonary Disease: Two Randomised Clinical Trials,” <i>Lancet</i>, 2009, 374(9691):685-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/19716960/pubmed" id="19716960" target="_blank">19716960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21563134">
<a name="21563134"></a>Chong J, Poole P, Leung B, et al, "Phosphodiesterase 4 Inhibitors for Chronic Obstructive Pulmonary Disease," <i>Cochrane Database Syst Rev</i>, 2011, 5:CD002309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/21563134/pubmed" id="21563134" target="_blank">21563134</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Daliresp (roflumilast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2020.</div>
</li>
<li>
<div class="reference">
                  Daxas (roflumilast) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed May 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18307529">
<a name="18307529"></a>Herbert C, Hettiaratchi A, Webb DC, et al, “Suppression of Cytokine Expression by Roflumilast and Dexamethasone in a Model of Chronic Asthma,” <i>Clin Exp Allergy</i>, 2008, 38(5):847-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/18307529/pubmed" id="18307529" target="_blank">18307529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25684586">
<a name="25684586"></a>Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet</i>. 2015;385(9971):857-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/25684586/pubmed" id="25684586" target="_blank">25684586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21272339">
<a name="21272339"></a>Rennard SI, Calverley PM, Goehring UM, et al, "Reduction of Exacerbations by the PDE4 Inhibitor Roflumilast -- The Importance of Defining Different Subsets of Patients With COPD," <i>Respir Res</i>, 2011, 12:18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/21272339/pubmed" id="21272339" target="_blank">21272339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20226872">
<a name="20226872"></a>Sabatini F, Petecchia L, Boero S, et al, “A Phosphodiesterase 4 Inhibitor, Roflumilast N-Oxide, Inhibits Human Lung Fibroblast Functions <i>in vitro</i>,” <i>Pulm Pharmacol Ther</i>, 2010, 23(4):283-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/20226872/pubmed" id="20226872" target="_blank">20226872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17704822">
<a name="17704822"></a>Sanz MJ, Cortijo J, Taha MA, et al, “Roflumilast Inhibits Leukocyte-Endothelial Cell Interactions, Expression of Adhesion Molecules and Microvascular Permeability,” <i>Br J Pharmacol</i>, 2007, 152(4):481-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/roflumilast-systemic-drug-information/abstract-text/17704822/pubmed" id="17704822" target="_blank">17704822</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139288 Version 72.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
